Ecco cosa dice il Goodman & Gilman ( la bibbia della farmacologia mondiale) sugli inibitore della dht-riduttasi:
5a-Reductase Inhibitors. Finasteride (PROSCAR) is an antagonist of 5a-reductase, especially type
II; dutasteride (AVODART) is an antagonist of types I and II; both drugs block the conversion of
testosterone to dihydrotestosterone, especially in the male external genitalia. These agents were
developed to treat benign prostatic hyperplasia, and they are approved in the United States and many
other countries for this purpose. When they are administered to men with moderately severe
symptoms due to obstruction of urinary tract outflow, serum and prostatic concentrations of
dihydrotestosterone decrease, prostatic volume decreases, and urine flow rate increases (McConnell
et al., 1998; Roehrborn et al., 2004; Clark et al., 2004). Impotence is a well-documented, albeit
infrequent, side effect of this use, although the mechanism is not understood. Finasteride also is
approved for use in the treatment of male pattern baldness under the trade name PROPECIA, even
though that effect is presumably mediated via type I 5a-reductase. Finasteride appears to be as
effective as flutamide and the combination of estrogen and cyproterone in the treatment of hirsutism
(Venturoli et al., 1999).
Praticamenete sostiene che è l'inibizione dell'enzima di tipo I e non quello di tipo II ad avere effetti sull'alopecia (ricordo che a livello del cuoio capelluto è presente l'isoenzima di tipo 2).
Quindi sembrerebbe che un inibitore specifico dell'enzima di tipo I (come l'acido azelaico) potrebbe avere benefici effetti, FORSE SOPRATTUTTO IN CHI NON HA AVUTO RISULTATI CON LA FINASTERIDE.
5a-Reductase Inhibitors. Finasteride (PROSCAR) is an antagonist of 5a-reductase, especially type
II; dutasteride (AVODART) is an antagonist of types I and II; both drugs block the conversion of
testosterone to dihydrotestosterone, especially in the male external genitalia. These agents were
developed to treat benign prostatic hyperplasia, and they are approved in the United States and many
other countries for this purpose. When they are administered to men with moderately severe
symptoms due to obstruction of urinary tract outflow, serum and prostatic concentrations of
dihydrotestosterone decrease, prostatic volume decreases, and urine flow rate increases (McConnell
et al., 1998; Roehrborn et al., 2004; Clark et al., 2004). Impotence is a well-documented, albeit
infrequent, side effect of this use, although the mechanism is not understood. Finasteride also is
approved for use in the treatment of male pattern baldness under the trade name PROPECIA, even
though that effect is presumably mediated via type I 5a-reductase. Finasteride appears to be as
effective as flutamide and the combination of estrogen and cyproterone in the treatment of hirsutism
(Venturoli et al., 1999).
Praticamenete sostiene che è l'inibizione dell'enzima di tipo I e non quello di tipo II ad avere effetti sull'alopecia (ricordo che a livello del cuoio capelluto è presente l'isoenzima di tipo 2).
Quindi sembrerebbe che un inibitore specifico dell'enzima di tipo I (come l'acido azelaico) potrebbe avere benefici effetti, FORSE SOPRATTUTTO IN CHI NON HA AVUTO RISULTATI CON LA FINASTERIDE.